HERON THERAPEUTICS, INC. /DE/ Amortization of Debt Issuance Costs
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Amortization of Debt Issuance Costs of $73.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-02-26
- HERON THERAPEUTICS, INC. /DE/ amortization of debt issuance costs for the quarter ending 2025-12-31 was -$35.00K, a 166.04% decline year-over-year.
- HERON THERAPEUTICS, INC. /DE/ amortization of debt issuance costs for the quarter ending 2025-09-30 was $2.00K, a 96.23% decline year-over-year.
- HERON THERAPEUTICS, INC. /DE/ amortization of debt issuance costs for the quarter ending 2025-06-30 was $53.00K, a 1.92% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ amortization of debt issuance costs for the quarter ending 2025-03-31 was $53.00K, a 1.92% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ amortization of debt issuance costs for fiscal 2025 was $73.00K, a 65.24% decline from fiscal 2024.
- HERON THERAPEUTICS, INC. /DE/ amortization of debt issuance costs for fiscal 2024 was $210.00K, a 1.94% increase from fiscal 2023.
- HERON THERAPEUTICS, INC. /DE/ amortization of debt issuance costs for fiscal 2023 was $206.00K, a 1.98% increase from fiscal 2022.
- HERON THERAPEUTICS, INC. /DE/ amortization of debt issuance costs for fiscal 2022 was $202.00K, a 69.75% increase from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$33.00K derived: sum of 2 quarters · filed 2026-02-26 | $20.00K derived: sum of 3 quarters · filed 2026-02-26 | $73.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $55.00K derived: sum of 2 quarters · filed 2025-11-04 | $108.00K 10-Q · filed 2025-11-04 | $161.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | $53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $106.00K 10-Q · filed 2025-08-08 | $159.00K derived: sum of 3 quarters · filed 2026-02-26 | $212.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | $53.00K 10-Q · filed 2025-05-06 | $106.00K derived: sum of 2 quarters · filed 2026-02-26 | $159.00K derived: sum of 3 quarters · filed 2026-02-26 | $211.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $106.00K derived: sum of 2 quarters · filed 2026-02-26 | $158.00K derived: sum of 3 quarters · filed 2026-02-26 | $210.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $105.00K derived: sum of 2 quarters · filed 2025-11-04 | $157.00K 10-Q · filed 2025-11-04 | $208.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $104.00K 10-Q · filed 2025-08-08 | $155.00K derived: sum of 3 quarters · filed 2026-02-26 | $207.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $52.00K 10-Q · filed 2025-05-06 | $103.00K derived: sum of 2 quarters · filed 2026-02-26 | $155.00K derived: sum of 3 quarters · filed 2026-02-26 | $207.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $103.00K derived: sum of 2 quarters · filed 2026-02-26 | $155.00K derived: sum of 3 quarters · filed 2026-02-26 | $206.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $104.00K derived: sum of 2 quarters · filed 2024-11-12 | $155.00K 10-Q · filed 2024-11-12 | $205.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $103.00K 10-Q · filed 2023-08-14 | $153.00K derived: sum of 3 quarters · filed 2025-02-27 | $205.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $51.00K 10-Q · filed 2024-05-07 | $101.00K derived: sum of 2 quarters · filed 2025-02-27 | $153.00K derived: sum of 3 quarters · filed 2025-02-27 | $203.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $102.00K derived: sum of 2 quarters · filed 2025-02-27 | $152.00K derived: sum of 3 quarters · filed 2025-02-27 | $202.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $102.00K derived: sum of 2 quarters · filed 2023-11-14 | $152.00K 10-Q · filed 2023-11-14 | $202.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $100.00K 10-Q · filed 2023-08-14 | $150.00K derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $50.00K 10-Q · filed 2023-05-11 | $100.00K derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $119.00K 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $69.00K 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |